dual anti-BCMA/anti-MICA/B CAR NK-cell therapy (Fate Therapeutics/Max-Delbruck-Center for Molecular Medicine/Harvard Medical School)

N/A

Report date: 2025/01/26 18:09:16

Base Information

Drug Namedual anti-BCMA/anti-MICA/B CAR NK-cell therapy (Fate Therapeutics/Max-Delbruck-Center for Molecular Medicine/Harvard Medical School)
Drug Alias Namedual anti-BCMA/anti-MICA/B CAR iNK-cell therapy (Fate Therapeutics/Max-Delbruck-Center for Molecular Medicine/Harvard Medical School)allogeneic iPSC-derived dual CAR iNK-cells (Fate Therapeutics/Max-Delbruck-Center for Molecular Medicine/Harvard Medical School)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulatorsMHC class I polypeptide-related sequence A modulatorsMHC class I polypeptide-related sequence B modulators
TargetsMHC class I polypeptide-related sequence BTumor necrosis factor ligand superfamily member 13MHC class I polypeptide-related sequence A
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMax Delbruck Centrum Fur Molekulare MedizinFate Therapeutics IncHarvard Medical School
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A